Emerald creates brands that support diverse customer needs. From our established medical product portfolio to our ever-expanding recreational brands, Emerald is focused on developing excellent products that you can trust.
SYNC™ Wellness is dedicated to helping create balance in everyday life through innovative “smoke-free” cannabis products that are discreet and made with natural ingredients. Enjoy SYNC products any time of day with the confidence of precise and defined dosing. Focused on a holistic approach to cannabis consumption to fit your lifestyle, you will be able to incorporate SYNC into your everyday wellness routine.
Emerald is passionate about growing healthy and flavourful whole-flower cannabis. Our team of expert agronomists at our state-of-the-art craft facility in Saint-Eustache, Québec, is focused on producing cultivars with optimal terpene profiles in a range of THC and CBD potencies. Emerald’s whole-flower cannabis is sold across Canada in various formats; look for our products in your favourite licensed retail shops and provincial cannabis stores.
Emerald has dedicated over six years to creating controlled, precise and predictable products to help people with everyday medical conditions live better lives.
Learn more about Emerald’s established medical products and start shopping for your prescription today.
© Copyright 2020 | All Rights Reserved | Privacy Policy | Terms and Conditions | Whistleblower Policy
Mr. Bovenschen has over 16 years of progressive experience in financial management, project and operations management, strategy development and risk management. Before joining Emerald, he was a senior member of the construction joint venture responsible for the Riyadh metro project, a rapid transit system under construction in Saudi Arabia with a US$22B contract value. Mr. Bovenschen previously served in various management roles for Strukton, a leading construction and engineering firm in the Netherlands and earned a Master of Business Administration from Nyenrode Business University and a BBA from NCOI in Utrecht, Netherlands.
Ms. Wong has over 30 years of quality and regulatory management experience in pharmaceutical and life science companies regulated to Canadian, US, European and international requirements. She has been responsible for establishing quality systems and ensuring regulatory compliance through all phases of product development from GPP, GLP, GCP, GMP for cannabis, pharmaceuticals, medical devices, combination products and biologicals. She was previously Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.) and worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.
Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.
Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.
He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.
Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.
